To: All persons and/or entities who purchased or otherwise acquired any shares of the common stock of CTI BioPharma Corp. [CTIC] during the period from March 9, 2015 to February 9, 2016 and were damaged thereby; a settlement has been announced in the securities litigation known as In re CTI BioPharma Corp. Securities Litigation, 2:16-cv-00216-RSL, filed in the United States District Court for the Western District of Washington. For additional information about this settlement, please see the Notice and Proof of Claim (links provided below):

• Notice of Pendency and Proposed Settlement of Class Action and Settlement Fairness Hearing;
• Proof of Claim and Release.

Claim submission deadline is February 20, 2018.

If you have any questions about the settlement, please contact the Claims Administrator. Their contact information can be found in the attached Notice.